The shares are listed on the Nasdaq Global Market

Davis Polk advised the sales agents in connection with the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $150 million. The common stock is listed on the Nasdaq Global Market under the symbol “RAPT.”

RAPT is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.

The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye, Savannah J. Dowling and Christian Mueller. All members of the Davis Polk team are based in the Northern California office.